Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Persson, Louise J P ^a   Aanerud, Marianne ^a   Hardie, Jon A ^b   Nilsen, Roy Miodini ^a   Bakke, Per S ^b   Eagan, Tomas M ^a,b   Hiemstra, Pieter S ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHELICIDIN; INTERLEUKIN 6; INTERLEUKIN 8; POLYPEPTIDE ANTIBIOTIC AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; VITAMIN D; CATHELICIDIN ANTIMICROBIAL PEPTIDE; CYTOKINE;

ADULT; AGE; ARTICLE; BACTERIAL COLONIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RISK; SMOKING; SPUTUM ANALYSIS; SPUTUM LEVEL; AGED; BLOOD; CASE CONTROL STUDY; CHEMISTRY; HAEMOPHILUS INFECTION; INFLAMMATION; NORWAY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SPUTUM; STATISTICAL MODEL;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CATHELICIDINS; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HAEMOPHILUS INFECTIONS; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SPUTUM; VITAMIN D;

EID: 85032380190     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01328-2016     Document Type: Article

References (37)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555.
2. Mullerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015; 147: 999–1007.
3. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009; 4: 435–459.
4. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015–1026.
5. Hiemstra PS, Amatngalim GD, van der Does AM, et al. Antimicrobial peptides and innate lung defenses: role in infectious and noninfectious lung diseases and therapeutic applications. Chest 2016; 149: 545–551.
6. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909–2912.
7. Hansdottir S, Monick MM, Hinde SL, et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008; 181: 7090–7099.
8. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010; 42: 635–643.
9. Seiler F, Lepper PM, Bals R, et al. Regulation and function of antimicrobial peptides in immunity and diseases of the lung. Protein Pept Lett 2014; 21: 341–351.
10. Bucki R, Byfield FJ, Janmey PA. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 2007; 29: 624–632.
11. Kilsgard O, Andersson P, Malmsten M, et al. Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities. Am J Respir Cell Mol Biol 2012; 46: 240–248.
12. Felgentreff K, Beisswenger C, Griese M, et al. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006; 27: 3100–3106.
13. Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001; 276: 33345–33352.
14. Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009; 183: 8148–8156.
15. Golec M, Reichel C, Mackiewicz B, et al. Cathelicidin LL-37, granzymes, TGF-beta1 and cytokines levels in induced sputum from farmers with and without COPD. Ann Agric Environ Med 2009; 16: 289–297.
16. Jiang YY, Xiao W, Zhu MX, et al. The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease. Respir Med 2012; 106: 1680–1689.
17. Xiao W, Hsu YP, Ishizaka A, et al. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005; 128: 2316–2326.
18. Tsoumakidou M, Bouloukaki I, Thimaki K, et al. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Exp Lung Res 2010; 36: 373–380.
19. Parameswaran GI, Wrona CT, Murphy TF, et al. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009; 9: 178.
20. Parameswaran GI, Sethi S, Murphy TF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 2011; 140: 611–617.
21. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 1117–1124.
22. Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010; 35: 540–548.
23. Tangedal S, Aanerud M, Persson LJ, et al. Comparison of inflammatory markers in induced and spontaneous sputum in a cohort of COPD patients. Respir Res 2014; 15: 138.
24. Tjabringa GS, Vos JB, Olthuis D, et al. Host defense effector molecules in mucosal secretions. FEMS Immunol Med Microbiol 2005; 45: 151–158.
25. van der Does AM, Beekhuizen H, Ravensbergen B, et al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol 2010; 185: 1442–1449.
26. van Wetering S, van der Linden AC, van Sterkenburg MA, et al. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med 2000; 48: 359–366.
27. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1993; 265: L286–L292.
28. Betsuyaku T, Takeyabu K, Tanino M, et al. Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. Eur Respir J 2002; 19: 1051–1057.
29. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999; 160: 1968–1975.
30. Herr C, Beisswenger C, Hess C, et al. Suppression of pulmonary innate host defence in smokers. Thorax 2009; 64: 144–149.
31. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010; 35: 1209–1215.
32. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.
33. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114–120.
34. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36–41.
35. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691–702.
36. Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol 2014; 14: 827–835.
37. Abou Alaiwa MH, Reznikov LR, Gansemer ND, et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials beta-defensin-3 and LL-37. Proc Natl Acad Sci USA 2014; 111: 18703–18708.